3D InSight™ Cytotoxicity Assay Kit incorporates Promega technology to measure cell viability in 3D microtissues, offering complete solution for toxicity and efficacy testing.
InSphero AG, the leading provider of 3D cell culture technology, assay-ready 3D microtissues, and 3D-focused contract research testing services, announced today the release of their new 3D InSight™ Cytotoxicity Assay Kit . The biochemical assay incorporates proprietary luminescent detection technology with improved reagent stability developed by Promega Corporation (Madison, WI) for measurement of cell viability in 3D microtissues. The kit provides customers with the convenience of ordering InSphero’s 3D InSight™ microtissues, specially formulated culture media, and an industry-standard cell viability assay from a single source, offering a complete solution for more predictive assessment of drug-induced liver injury (DILI), general toxicity and drug efficacy.
3D liver and tumor microtissues are increasingly used to meet the demands of drug discovery and development, serving as more representative and predictive biological ...
